Sign up Australia
Proactive Investors - Run By Investors For Investors

Zelda Therapeutics expands pipeline of opportunities

Zelda is a California-founded biotech focused on medical cannabis therapies.
Zelda Therapeutics expands pipeline of opportunities
Today's agreement with help accelerate valuable research

Zelda Therapeutics (ASX:ZLD) continues to leverage world-class knowledge and expertise in the medical cannabis sector.

A new license agreement with Caziwell Inc increases flexibility to expand the clinical trial program.

The agreement provides significant immediate and long-term financial benefits for Zelda and replaces the existing agreement.

Harry Karelis, executive chairman for Zelda, commented:

“The restructuring of the Caziwell Licence Agreement provides a meaningful positive impact to Zelda shareholders by reducing future financial obligations it would have incurred through executing its clinical trials strategy.

"With these amendments in place, Zelda moves closer to industry standards for agreements of this nature.

"We have a full pipeline of opportunities ahead of us and reducing future expenses helps extend our financial capacity to progress these projects.

"We have a very exciting year ahead."


New license agreement benefits

- Zelda maintains exclusive access to patient data, formulations and protocols for use in its current research activities;
- Positive impact on cashflow, with an immediate $200,000 saving;
- Permanent reduction in future royalty and sub-licence fees; and
- Significantly increases flexibility to expand clinical trial program.


Trials

Zelda has embarked on a program of human clinical trials initially in sleep disorder (insomnia) and eczema indications.

In addition, Zelda is building a pre-clinical research portfolio targeting cancer.


World-leading Scientific Advisory Board

Prof. Manuel Guzman: Full Professor of Biochemistry and Molecular Biology at Madrid’s Complutense University and expert on the molecular mechanisms of action and role of cannabinoids in controlling cell generation and death.

Dr Cristina Sanchez: Assistant Professor at Complutense University, Madrid Spain. Specialist in the area of lipid signaling, including cannabinoids in an oncology setting.

Dr Joe Goldstrich: Distinguished clinical career in preventive cardiology and nutrition spanning over 40 years. He has evaluated over 3,500 patients in the US using cannabis as a fundamental medicine in the management of a variety of medical conditions.

Dr Noah Federman: Highly respected paediatric clinical and research oncologist. Currently, Director of the Paediatric Bone and Soft Tissue Sarcoma Program at University of California, part of the prestigious UCLA Sarcoma Program and UCLA's Jonsson Comprehensive Cancer Centre.


Analysis

Zelda continues to expand its relationships and agreements in the sector.

The company has a strong background in medical cannabis, and was formed to fund clinical efficacy trials developed by its U.S. partner, Aunt Zelda, and used to treat a range of diseases showing strong efficacy data.

Investors are recognising the potential since the listing (via RTO) in November 2016, where shares could be purchased at $0.025 in the $4 million raising.

Since then Zelda has more than tripled in value, last trading at $0.085 per share.





Register here to be notified of future ZLD Company articles
View full ZLD profile View Profile

Zelda Therapeutics Ltd Timeline

Related Articles

Proteomics International Laboratories: Access latest PPT from Proactive's CEO Sessions
April 13 2017
Richard Lipscombe talked revenue generation and growth path with investors.
Woman with tissue facing pollen
Fri
Allergy, which saw its market share grow by a percentage point to 13%, is in a strong financial position, with £22.1mln in the bank
eye-766166_1280_583251a48f148.jpg
November 21 2016
The flagship product, CardioCel, is a bio-engineered tissue scaffold used in the heart valve repair market.

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use